BioVersys’ new medicine would be used as a stand-alone to treat uncomplicated skin and skin structure infections (SSSI) or in combination with antibiotics for more severe infections
(BOSTON) – CARB-X is awarding BioVersys AG, headquartered in Basel, Switzerland, up to US $3.94 million in non-dilutive funding, with the possibility of up to $4.98 million more if certain project milestones are met, to develop new drugs designed to disarm Staphylococcus aureus bacteria of virulence factors that can cause serious skin infections and can spread to muscles, lungs and other body parts. The molecules are in development as a stand-alone therapy and for use in combination with existing antibiotics.
“Drug-resistant bacteria represent one of the greatest threats to public health globally. New approaches, like the BioVersys’ project, are urgently needed to help save lives and to curb the spread of drug-resistant bacteria,” said Kevin Outterson, Executive Director of CARB-X, which is based at the Boston University School of Law. “This project is in early stages of development but if successful and approved for use in patients, it would represent tremendous progress in the fight against drug resistance, by offering an alternative therapy to traditional antibiotics and also restoring the effectiveness of existing antibiotics.”